Reminder: Ligand to Host Analyst Day on November 14th in New York City
November 06 2017 - 9:00AM
Business Wire
Event to feature business updates and
presentations by three corporate partners
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will
host an Analyst Day on Tuesday, November 14, 2017 from 4:00 p.m. to
5:30 p.m. Eastern time (1:00 p.m. to 2:30 p.m. Pacific time) in New
York City.
Company presenters will include John Higgins, CEO, Matt Foehr,
President and COO, and Matt Korenberg, CFO. In addition, scientific
presentations will be given by members of Ligand’s research team
including Roland Buelow, Ph.D., Vice President, Antibody
Technologies and Eric Vajda, Ph.D., Vice President, Preclinical
Research and Development.
Ligand has over 95 corporate partners advancing 160
Shots-on-Goal (fully funded programs). For this event, Ligand has
invited representatives of three companies to talk about their
programs that are partnered with Ligand. These programs incorporate
Ligand’s Captisol technology or novel small-molecule drug programs,
and all are included in Ligand’s “Next 12” portfolio programs. The
presenting partners will be:
- David Portman, M.D., CEO of Sermonix
Pharmaceuticals, discussing lasofoxifene, a selective estrogen
receptor modulator (SERM) being developed for treatment of advanced
breast cancer
- Brian Lian, Ph.D., CEO of Viking
Therapeutics, discussing VK5211, a selective androgen receptor
modulator (SARM) being developed for rehabilitation post-hip
fracture and VK2809, a selective thyroid receptor-β agonist being
developed to treat metabolic disease
- Lyn Baranowski, Senior Vice President,
Corporate Development and Strategy at Melinta Therapeutics,
discussing Baxdela™ (delafloxacin), a novel antibiotic approved in
June 2017 in adults for the treatment of acute bacterial skin and
skin structure infections caused by susceptible bacteria
Ligand’s company presentations will cover the following
topics:
- Update on Ligand’s business model and
financials, expanded product portfolio, technology platforms and
intellectual property
- Overview of partner and license
portfolio and highlights of the Big 6 and Next 12 programs
- Outlook for the OmniAb® antibody
discovery business incorporating the newly-acquired OmniChicken™
technology
- Update on the Glucagon Receptor
Antagonist (GRA) development program for Type 2 diabetes including
a review of results from the recently-completed Phase 2 trial
- Overview of estimated 2017 year-end
financial results and commentary on the financial outlook for
2018
The event will be webcast live and can be accessed at
www.ligand.com. A replay of this webcast will be available for 90
days following the event. For more information or to reserve a
seat, please contact Ani Mikaelian at amikaelian@lhai.com.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono-and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171106005480/en/
Ligand Pharmaceuticals IncorporatedTodd Pettingill, (858)
550-7500investors@ligand.com@Ligand_LGNDorLHABruce Voss, (310)
691-7100bvoss@lhai.com
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Sep 2023 to Sep 2024